Fabrication of a Novel Au Star@AgAu Yolk-Shell Nanostructure for Ovarian Cancer Early Diagnosis and Targeted Therapy
Ting Lan,Yang Zhao,Yu Du,Chunyi Ma,Rui Wang,Qianlei Zhang,Shanshan Wang,Wenxian Wei,Honghua Yuan,Qingli Huang
DOI: https://doi.org/10.2147/ijn.s413457
IF: 7.033
2023-07-11
International Journal of Nanomedicine
Abstract:Ting Lan, 1, &ast Yang Zhao, 1, 2, &ast Yu Du, 1, 3, &ast Chunyi Ma, 1 Rui Wang, 1 Qianlei Zhang, 1 Shanshan Wang, 1 Wenxian Wei, 4 Honghua Yuan, 2 Qingli Huang 1, 2 1 Medical Technology School of Xuzhou Medical University, Xuzhou City, Jiangsu, 221000, People's Republic of China; 2 Public Experimental Research Center of Xuzhou Medical University, Xuzhou City, Jiangsu, 221004, People's Republic of China; 3 Xuzhou Center for Disease Control and Prevention, Xuzhou City, Jiangsu, 221006, People's Republic of China; 4 Testing Center, Yangzhou University, Yangzhou City, Jiangsu, 225009, People's Republic of China &astThese authors contributed equally to this work Correspondence: Honghua Yuan, Public Experimental Research Center of Xuzhou Medical University, Tong Shan No. 209, Xuzhou, 221004, People's Republic of China, Tel/Fax +86-516-83262091, Email Qingli Huang, Medical Technology School, Public Experimental Research Center of Xuzhou Medical University, Tong Shan No. 209, Xuzhou, 221004, People's Republic of China, Tel/Fax +86-516-83262091, Email Purpose: A novel CYPA-targeted, SiO 2 encapsulated Au yolk-shell nanostructure (YSNS) was synthesized and used for ovarian cancer early diagnosis and therapy. Methods: Diverse spectroscopic and microscopic methods were utilized to investigate the pattern of the yolk-shell nanostructure. In addition, in vitro and in vivo experiments were carried out. Results: It can be found that the ratio of HAuCl 4 and AgNO 3 played a critical role in the constitution of the yolk-shell nanostructure. The as-prepared yolk-shell nanostructure showed excellent SERS performance, which could be utilized as SERS substrate for specific sensitivity analysis of ovarian cancer markers cyclophilin A (CYPA) with detectable limit of 7.76&ast10 − 10 μg/mL. In addition, the as-prepared yolk-shell nanostructure possessed outstanding photothermal performance, which could be used as photothermal agent for ovarian cancer therapy. Experiments in vitro and in vivo proved that the as-prepared yolk-shell nanostructures are ideal candidate for early diagnosis and therapy for ovarian cancer in one platform. Conclusion: This work holds promise to offer a new method for the detection and therapy of ovarian cancer in the early stage. Graphical Keywords: yolk-shell nanostructure, surface-enhanced Raman scattering, early diagnosis, cancer targeted therapy Graphical There are numerous genital tumors that threaten women's health around the world, one among them is ovarian cancer. In 2022, the American Cancer Society estimates that an additional 19,880 women will suffer from ovarian cancer and 12,810 deaths. 1 In the early stage, the clinical symptoms of ovarian cancer are relatively hidden and difficult to be detected, so most patients cannot be diagnosed until the advanced stage, missing the best treatment opportunity. 2,3 Therefore, it is urgent to explore the effective biomarkers and methods for diagnosis of the early stage of ovarian cancer. Currently, there are only a few publicly recognized ovarian cancer tumor markers, carbohydrate antigen 125 (CA125) and humanepididymisprotein4 (HE4) which were most used in clinical. 4–7 However, when the stage of benign ovarian cyst, hysteromyoma, infection, the sensitivity and specificity are poorer, the overall showed a trend of increase [8]. According to previous reports and our research, the concentration of CYPA in patients with early ovarian cancer was significantly increased, compared with healthy women and benign group, and the proportion of CYPA positive reaction was higher in I/II stage. 8–10 In addition, the secretion of CYPA in serous ovarian cancer is much higher than that in nearby tissues, and the advanced of ovarian cancer is also closely related to the expression of CYPA. 10 All these indicate that the overexpression of CYPA is intimately associated with the occurrence of ovarian cancer. At present, most of the detection methods of CYPA are chemiluminescence and ELISA, but their detection limit is about 10 −4 –10 −5 μg/mL, which makes its clinical application in early diagnosis of tumors greatly limited. 4,11–14 Surface-enhanced Raman spectroscopy (SERS) is an ideal approach to solving problems above attributed to its high sensitivity, straightforward, and simple, which has been extensively studied and applied in medical diagnosis, chemistry, biology, environment and other fields. 15 -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology